Investor Firm Challenges Lisata Therapeutics–Kuva Deal Over Non‑Tradeable CVRs
- Halper Sadeh is probing Lisata’s proposed sale to Kuva Labs, alleging securities‑law violations and fiduciary breaches.
- Deal’s $4 cash plus two non‑tradeable CVRs may reduce shareholder liquidity, lack disclosure, and discourage competing bids.
- Firm seeks higher consideration, more disclosures or renegotiation, urging Lisata shareholders to contact them for evaluation.
Investor law firm challenges Lisata-Kuva terms amid scrutiny of biotech deal
Halper Sadeh LLC is probing Lisata Therapeutics’ proposed sale to Kuva Labs, raising concerns that the transaction’s structure may violate federal securities laws and breach directors’ fiduciary duties. The New York‑based investor‑rights firm says the deal — $4.00 per share in cash plus two non‑tradeable contingent value rights (CVRs) payable only if certain conditions are met — may leave ordinary Lisata shareholders exposed while insiders secure outsized benefits or protections.
The firm singles out the non‑tradeable CVRs as a potential point of unfairness and opacity. Because such instruments cannot be sold on markets, Halper Sadeh says they can materially reduce the liquidity and economic value available to shareholders compared with straightforward cash or tradable securities, and that disclosure about the CVRs’ triggers and valuation may be insufficient. The complaint frames these features alongside provisions that could discourage superior competing bids, which, if accurate, may amount to breaches of the board’s duty to seek the best reasonably available value for shareholders.
Halper Sadeh indicates it may seek increased consideration, additional disclosures, or other relief on behalf of Lisata investors. The firm is asking affected shareholders to come forward so it can evaluate claims and, if warranted, press for remedies that could include renegotiation of deal terms or supplemental information intended to improve transparency and shareholder bargaining power in biotech M&A transactions.
Broader review of contemporaneous deals
Halper Sadeh is conducting similar reviews of several other proposed transactions, including RAPT Therapeutics’ sale to GSK, Allegiant Travel’s merger with Sun Country Airlines and Mission Produce’s merger with Calavo Growers. The firm warns that executives and certain insiders in those deals may also receive protections or payments not shared with the broader shareholder base and that deal terms may constrain competing offers.
The firm emphasizes it represents clients on a contingent fee basis and invites shareholders of Lisata, RAPT, Allegiant or Mission to contact its New York office for a free case evaluation. Halper Sadeh lists attorneys Daniel Sadeh and Zachary Halper as contacts and provides a firm website for more information.
